Ganglioside complexes as new target antigens in Guillain-Barré syndrome.
about
Emerging drugs for Guillain-Barré syndromeGuillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosisBiomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be ExploredMapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous systemUpdate on Guillain-Barré syndromeAcute pan-dysautonomia as well as central nervous system involvement and peripheral neuropathies in a patient with systemic lupus erythematosus.Antibodies to single glycolipids and glycolipid complexes in Guillain-Barré syndrome subtypesGuillain-Barré syndrome-related Campylobacter jejuni in Bangladesh: ganglioside mimicry and cross-reactive antibodies.Antibodies to heteromeric glycolipid complexes in Guillain-Barré syndrome.Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseasesComplex of GM1- and GD1a-like lipo-oligosaccharide mimics GM1b, inducing anti-GM1b antibodies.Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain-Barre and Miller Fisher syndromes.Anti-GQ1b antibody syndrome: anti-ganglioside complex reactivity determines clinical spectrum.Anti-ganglioside complex antibodies in Miller Fisher syndromeThe immunobiology of Guillain-Barré syndromes.Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains.Ganglioside GM2/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82/cMet-mediated pathway.Gangliosides as targets for autoimmune injury to the nervous system.The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice.Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review.Microarray screening of Guillain-Barré syndrome sera for antibodies to glycolipid complexes.Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.Guillain-Barré syndrome: update on immunobiology and treatment.Sphingolipid topology and the dynamic organization and function of membrane proteins.Antibodies against ganglioside complexes in Guillain-Barré syndrome and related disorders.Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies.Carbohydrate to carbohydrate interaction in development process and cancer progression.Recent developments and future directions in Guillain-Barré syndrome.Dissecting the Role of Anti-ganglioside Antibodies in Guillain-Barré Syndrome: an Animal Model Approach.Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment.Guillain-Barré syndrome: a century of progress.Autoantibody pathogenicity in a multifocal motor neuropathy induced pluripotent stem cell-derived model.Diagnostic Utility of Auto Antibodies in Inflammatory Nerve Disorders.Ganglioside complexes as targets for antibodies in Miller Fisher syndrome.Guillain-Barré syndrome with antibodies to GD1a/GD1b complex.Analysis of lectin binding to glycolipid complexes using combinatorial glycoarrays.Primary central nervous system lymphoma mimicking Bickerstaff's encephalitis.Harmful effects of anti-GalNAc-GD1a antibodies and TNF-alpha on rat dorsal root ganglia.Anti-sulfatide/galactocerebroside antibodies in immunoglobulin M paraproteinemic neuropathies.Diagnostics of dysimmune peripheral neuropathies.
P2860
Q22241376-0C60D6B8-8FC1-4836-AC85-0EA62DFBF1F5Q22251013-A07310CA-110F-4380-9788-E0838EA881FFQ26785669-8F2CE654-EA12-40BC-97C0-F13C395A87DFQ28075974-763DD672-8CDA-4993-8290-21EC3DE81596Q28293098-E538360E-744D-4151-BD9D-45B61D0C35EFQ33156360-BA79DFED-BD2F-4C55-BF82-5351230B7241Q33980125-EC8F8B8B-B829-40C4-BAD6-E791F1632081Q34405976-774A7930-0C42-4FA7-B8ED-520D87473B1CQ35072720-8EE884C0-988D-4596-9087-B4F9CE29689EQ35220367-B5A5529B-901C-41B2-8C15-EC0D6F3EDB66Q35389058-36C5BB36-D330-4F86-8BE3-7CE2FACFA9A1Q35689505-E15A09C2-10D9-4A86-9858-E0B90F4ABEAAQ35692197-E4E907B8-092C-4EA3-AB97-C6690BE91E27Q36143181-90C68EB3-345B-473E-A992-FF4F7C241E9CQ36164122-DF40755D-FBE3-40B3-A955-C1F4AFBDB920Q36559844-54C371EF-C771-4ABE-905F-71CAD2734553Q36882981-5B2E91E6-B970-45EA-AB35-91393C3D2D64Q36994582-1E8EBA9C-433A-4EB6-968A-3EBE3CDACE05Q37111379-79B0D997-1E0A-446A-B7FD-0DD308491525Q37207391-816E8722-E500-43E9-A3F0-312E0357335BQ37321485-015CFB4F-AC05-49CE-A7A2-CC9789D1CC1BQ37494674-130E57BD-8FCC-4EE0-8E19-46EF2A7DC8A5Q37600859-A6832E34-8465-4555-AC4A-5B35277BD09EQ37616697-84D3F0C6-27F0-4282-ADC6-710D36C78C05Q37826777-6C225B2C-16F7-42A4-B3B0-8EBB126F6F8CQ37959252-376F56D9-3C78-40B1-8B04-AF2773C555A5Q38011603-AA57FBD6-05A1-46BF-87AB-BB82D0161306Q38070887-DE351593-11FB-480B-BD16-5AC7FA9A69B6Q38587703-CE4030E0-884E-4178-A044-D2EFF7860703Q38862736-620FE564-6DDF-490A-B8BA-CA196BCFAF92Q39011456-9918FEEB-9CEA-4972-AC42-C9893F3BE248Q39808275-6B70FD77-F14D-494A-9038-94DEAF567AF1Q41189967-CFB134D7-B79B-422C-8BD1-3D773E9FEE7AQ42718665-F7092731-17B3-427A-B979-E65E8CB4C3C1Q42766054-DF63A37C-E0F9-4498-BBB2-F6E8D60A0A9EQ43120650-8745705C-82BA-4153-97BF-526C0F599E7CQ44122561-EA7A634C-1744-4911-B4AB-469D27669818Q46548667-73145853-94A2-49C1-A24E-34352EF11037Q48282126-86788164-D5E2-46CA-A5B3-5C0CBA987F3AQ50067515-9D72499A-8F05-48C0-8655-833442050ECF
P2860
Ganglioside complexes as new target antigens in Guillain-Barré syndrome.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Ganglioside complexes as new target antigens in Guillain-Barré syndrome.
@en
Ganglioside complexes as new target antigens in Guillain-Barré syndrome.
@nl
type
label
Ganglioside complexes as new target antigens in Guillain-Barré syndrome.
@en
Ganglioside complexes as new target antigens in Guillain-Barré syndrome.
@nl
prefLabel
Ganglioside complexes as new target antigens in Guillain-Barré syndrome.
@en
Ganglioside complexes as new target antigens in Guillain-Barré syndrome.
@nl
P2093
P2860
P356
P1433
P1476
Ganglioside complexes as new target antigens in Guillain-Barré syndrome.
@en
P2093
Daiji Morita
Kazuo Motoyoshi
Keiko Kamakura
Ken-ichi Kaida
Mami Kanzaki
Minako Hirakawa
P2860
P304
P356
10.1002/ANA.20222
P577
2004-10-01T00:00:00Z